Major Sponsors
Platinum:
Gold:
About Bristol Myers Squibb
Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular and neuroscience. Our employees work every day to transform patients’ lives through science.
About Pierre Fabre
Learn more at www.pierre-fabre.com.
About Sun Pharma
Sun Pharma dedicates a significant part of its revenue to researching and developing new and innovative products aiming at addressing high unmet clinical needs focusing on Dermatology and Dermato-Oncology.
The Western European Headquarters for the Specialty Business unit is based in near Amsterdam (The Netherlands).
Silver:
About Immunocore
We are a pioneering, clinical-stage T cell receptor biotechnology company working to develop and commercialize a new generation of transformative medicines to address unmet needs in cancer, infection, and autoimmune disease.
Our initial therapeutic focus is in oncology, where pivotal clinical trials are currently underway in metastatic uveal melanoma, a rare form of eye cancer.
We also have a robust pipeline of programs spanning a broad range of cancer indications, as well as infectious and autoimmune diseases.
For more information, please visit www.Immunocore.com
Bronze:
Sponsors & Exhibitors:
About Replimune
Replimune is pioneering a new class of oncolytic immunotherapies (OI) designed to ignite a powerful patient-specific immune response to treat cancer and vaccinate against future relapse. The company’s Immulytic™ platform is intended to achieve the holy grail of personalized anti-cancer treatments — combining multiple mechanisms of action to deliver therapies with the ability to not only directly kill tumors and generate systemic anti-cancer immune responses, but to also create a practical, in situ approach to achieving personalized systemic anti-cancer vaccination. The approach is expected to be highly synergistic with immune checkpoint blockade and other methods of treatment across a broad range of cancers. With deep experience across drug development and commercialization the Replimune team is now focused on delivering therapies to patients that are intended to be significant improvements compared to what was previously possible, and which will broaden the use of OI well beyond immune responsive cancers to the full range of solid tumor types. Since September 2015, Replimune has built a portfolio of product candidates with three programs currently in the clinic. Its lead program, RP1, is in two registration directed clinical trials – in cutaneous squamous cell carcinoma and anti-PD1 failed melanoma – and is also being tested in other tumor types, including anti-PD1 failed non-small cell lung cancer.
About Roche
Roche was founded on October 1st, 1896. The founder, Fritz Hoffmann-La Roche, was among the first to recognize that the industrial manufacture of standardized medicines would be a major advance in the fight against disease.
From the very beginning, Roche’s visionary founder focused his company on innovation and on establishing an international presence. This multinational presence reinforces our ability to offer our healthcare solutions and to anticipate needs in all regions of the world. Today, Roche employs more than 85,000 people and sells its products in more than 150 countries.
Today Roche ranks among the world’s leading healthcare companies and has two strong core businesses: diagnostics and pharmaceuticals.
Read more about our company in our image brochure "Doing now what patients need next".
For more information, please visit www.roche.com.
About Novartis
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 145 nationalities work at Novartis around the world.
For more information, please visit www.novartis.com.